nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—Methotrexate—esophageal cancer	0.4	1	CrCtD
Pralatrexate—SLC19A1—Methotrexate—esophageal cancer	0.0924	0.32	CbGbCtD
Pralatrexate—TYMS—Capecitabine—esophageal cancer	0.0723	0.25	CbGbCtD
Pralatrexate—FPGS—Methotrexate—esophageal cancer	0.0668	0.231	CbGbCtD
Pralatrexate—Folic Acid—Methotrexate—esophageal cancer	0.053	0.2	CrCrCtD
Pralatrexate—Pemetrexed—Methotrexate—esophageal cancer	0.053	0.2	CrCrCtD
Pralatrexate—Leucovorin—Methotrexate—esophageal cancer	0.053	0.2	CrCrCtD
Pralatrexate—Tetrahydrofolic acid—Methotrexate—esophageal cancer	0.053	0.2	CrCrCtD
Pralatrexate—Raltitrexed—Methotrexate—esophageal cancer	0.053	0.2	CrCrCtD
Pralatrexate—DHFR—Methotrexate—esophageal cancer	0.0339	0.117	CbGbCtD
Pralatrexate—TYMS—Methotrexate—esophageal cancer	0.0236	0.0817	CbGbCtD
Pralatrexate—SLC19A1—digestive system—esophageal cancer	0.0011	0.101	CbGeAlD
Pralatrexate—FPGS—bronchus—esophageal cancer	0.000949	0.0869	CbGeAlD
Pralatrexate—SLC19A1—lung—esophageal cancer	0.000919	0.0842	CbGeAlD
Pralatrexate—FPGS—trachea—esophageal cancer	0.000852	0.0781	CbGeAlD
Pralatrexate—FPGS—digestive system—esophageal cancer	0.000733	0.0672	CbGeAlD
Pralatrexate—SLC19A1—lymph node—esophageal cancer	0.000628	0.0576	CbGeAlD
Pralatrexate—TYMS—bronchus—esophageal cancer	0.000622	0.057	CbGeAlD
Pralatrexate—DHFR—bronchus—esophageal cancer	0.000616	0.0565	CbGeAlD
Pralatrexate—Renal failure chronic—Cisplatin—esophageal cancer	0.000613	0.116	CcSEcCtD
Pralatrexate—FPGS—lung—esophageal cancer	0.000612	0.0561	CbGeAlD
Pralatrexate—TYMS—smooth muscle tissue—esophageal cancer	0.000609	0.0558	CbGeAlD
Pralatrexate—DHFR—trachea—esophageal cancer	0.000553	0.0507	CbGeAlD
Pralatrexate—TYMS—digestive system—esophageal cancer	0.000481	0.0441	CbGeAlD
Pralatrexate—DHFR—digestive system—esophageal cancer	0.000476	0.0436	CbGeAlD
Pralatrexate—FPGS—lymph node—esophageal cancer	0.000419	0.0384	CbGeAlD
Pralatrexate—Leucovorin—ABCC2—esophageal cancer	0.000403	0.445	CrCbGaD
Pralatrexate—TYMS—lung—esophageal cancer	0.000401	0.0368	CbGeAlD
Pralatrexate—DHFR—lung—esophageal cancer	0.000397	0.0364	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Methotrexate—esophageal cancer	0.000326	0.0618	CcSEcCtD
Pralatrexate—TYMS—lymph node—esophageal cancer	0.000275	0.0252	CbGeAlD
Pralatrexate—DHFR—lymph node—esophageal cancer	0.000272	0.0249	CbGeAlD
Pralatrexate—Tetrahydrofolic acid—ABCC2—esophageal cancer	0.00026	0.287	CrCbGaD
Pralatrexate—Night sweats—Capecitabine—esophageal cancer	0.000225	0.0427	CcSEcCtD
Pralatrexate—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00018	0.0341	CcSEcCtD
Pralatrexate—Laryngeal pain—Capecitabine—esophageal cancer	0.000179	0.0338	CcSEcCtD
Pralatrexate—Methotrexate—ABCC2—esophageal cancer	0.000178	0.196	CrCbGaD
Pralatrexate—Body temperature increased—Carboplatin—esophageal cancer	0.000159	0.0301	CcSEcCtD
Pralatrexate—Dehydration—Cisplatin—esophageal cancer	0.000111	0.0211	CcSEcCtD
Pralatrexate—Hypokalaemia—Cisplatin—esophageal cancer	0.000109	0.0206	CcSEcCtD
Pralatrexate—Sepsis—Capecitabine—esophageal cancer	0.000106	0.02	CcSEcCtD
Pralatrexate—Pancytopenia—Cisplatin—esophageal cancer	9.84e-05	0.0186	CcSEcCtD
Pralatrexate—Pain in extremity—Capecitabine—esophageal cancer	8.84e-05	0.0167	CcSEcCtD
Pralatrexate—Dehydration—Capecitabine—esophageal cancer	8.22e-05	0.0156	CcSEcCtD
Pralatrexate—Liver function test abnormal—Capecitabine—esophageal cancer	8.16e-05	0.0154	CcSEcCtD
Pralatrexate—Hypokalaemia—Capecitabine—esophageal cancer	8.04e-05	0.0152	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	7.96e-05	0.0151	CcSEcCtD
Pralatrexate—Sepsis—Methotrexate—esophageal cancer	7.86e-05	0.0149	CcSEcCtD
Pralatrexate—Pancytopenia—Capecitabine—esophageal cancer	7.25e-05	0.0137	CcSEcCtD
Pralatrexate—Neutropenia—Capecitabine—esophageal cancer	7.14e-05	0.0135	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Capecitabine—esophageal cancer	7.1e-05	0.0134	CcSEcCtD
Pralatrexate—Anaemia—Cisplatin—esophageal cancer	6.67e-05	0.0126	CcSEcCtD
Pralatrexate—Methotrexate—ABCB1—esophageal cancer	6.54e-05	0.0722	CrCbGaD
Pralatrexate—Leukopenia—Cisplatin—esophageal cancer	6.46e-05	0.0122	CcSEcCtD
Pralatrexate—Epistaxis—Capecitabine—esophageal cancer	6.42e-05	0.0122	CcSEcCtD
Pralatrexate—Liver function test abnormal—Methotrexate—esophageal cancer	6.07e-05	0.0115	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	5.92e-05	0.0112	CcSEcCtD
Pralatrexate—Oedema—Cisplatin—esophageal cancer	5.89e-05	0.0112	CcSEcCtD
Pralatrexate—Thrombocytopenia—Cisplatin—esophageal cancer	5.77e-05	0.0109	CcSEcCtD
Pralatrexate—Tachycardia—Cisplatin—esophageal cancer	5.75e-05	0.0109	CcSEcCtD
Pralatrexate—Anorexia—Cisplatin—esophageal cancer	5.62e-05	0.0106	CcSEcCtD
Pralatrexate—Pancytopenia—Methotrexate—esophageal cancer	5.4e-05	0.0102	CcSEcCtD
Pralatrexate—Neutropenia—Methotrexate—esophageal cancer	5.32e-05	0.0101	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Methotrexate—esophageal cancer	5.28e-05	0.01	CcSEcCtD
Pralatrexate—Dyspnoea—Cisplatin—esophageal cancer	5.25e-05	0.00994	CcSEcCtD
Pralatrexate—Back pain—Capecitabine—esophageal cancer	5.15e-05	0.00974	CcSEcCtD
Pralatrexate—Decreased appetite—Cisplatin—esophageal cancer	5.12e-05	0.00969	CcSEcCtD
Pralatrexate—Anaemia—Capecitabine—esophageal cancer	4.92e-05	0.00931	CcSEcCtD
Pralatrexate—Epistaxis—Methotrexate—esophageal cancer	4.78e-05	0.00905	CcSEcCtD
Pralatrexate—Leukopenia—Capecitabine—esophageal cancer	4.76e-05	0.00901	CcSEcCtD
Pralatrexate—Body temperature increased—Cisplatin—esophageal cancer	4.66e-05	0.00881	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	4.65e-05	0.00161	CbGpPWpGaD
Pralatrexate—Cough—Capecitabine—esophageal cancer	4.64e-05	0.00879	CcSEcCtD
Pralatrexate—FPGS—Metabolism—GAPDH—esophageal cancer	4.64e-05	0.00161	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CRABP1—esophageal cancer	4.6e-05	0.00159	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—GSTT1—esophageal cancer	4.58e-05	0.00159	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SLC52A3—esophageal cancer	4.57e-05	0.00159	CbGpPWpGaD
Pralatrexate—FPGS—Disease—B2M—esophageal cancer	4.55e-05	0.00158	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CYP2A6—esophageal cancer	4.53e-05	0.00157	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—HIST1H2BM—esophageal cancer	4.51e-05	0.00156	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	4.5e-05	0.00156	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	4.45e-05	0.00154	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	4.44e-05	0.00154	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—RB1—esophageal cancer	4.4e-05	0.00153	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	4.4e-05	0.00153	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TP53—esophageal cancer	4.38e-05	0.00152	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GNG7—esophageal cancer	4.37e-05	0.00152	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KMT2D—esophageal cancer	4.36e-05	0.00151	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ENO1—esophageal cancer	4.36e-05	0.00151	CbGpPWpGaD
Pralatrexate—Oedema—Capecitabine—esophageal cancer	4.34e-05	0.00822	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—CDKN1A—esophageal cancer	4.3e-05	0.00149	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PSME2—esophageal cancer	4.3e-05	0.00149	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PSME1—esophageal cancer	4.3e-05	0.00149	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS1—esophageal cancer	4.29e-05	0.00149	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ENO1—esophageal cancer	4.29e-05	0.00149	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—MYC—esophageal cancer	4.29e-05	0.00149	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	4.27e-05	0.00148	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Capecitabine—esophageal cancer	4.25e-05	0.00805	CcSEcCtD
Pralatrexate—Tachycardia—Capecitabine—esophageal cancer	4.24e-05	0.00802	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—PSME2—esophageal cancer	4.23e-05	0.00147	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PSME1—esophageal cancer	4.23e-05	0.00147	CbGpPWpGaD
Pralatrexate—Asthenia—Cisplatin—esophageal cancer	4.23e-05	0.008	CcSEcCtD
Pralatrexate—Anorexia—Capecitabine—esophageal cancer	4.14e-05	0.00783	CcSEcCtD
Pralatrexate—FPGS—Disease—CALR—esophageal cancer	4.12e-05	0.00143	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ALDH2—esophageal cancer	4.1e-05	0.00142	CbGpPWpGaD
Pralatrexate—Diarrhoea—Cisplatin—esophageal cancer	4.03e-05	0.00763	CcSEcCtD
Pralatrexate—FPGS—Disease—FBXW7—esophageal cancer	3.99e-05	0.00138	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MAD2L1—esophageal cancer	3.98e-05	0.00138	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—HIST1H2BM—esophageal cancer	3.93e-05	0.00136	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PSME2—esophageal cancer	3.91e-05	0.00136	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PSME1—esophageal cancer	3.91e-05	0.00136	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GSTT1—esophageal cancer	3.9e-05	0.00135	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	3.89e-05	0.00135	CbGpPWpGaD
Pralatrexate—Dyspnoea—Capecitabine—esophageal cancer	3.87e-05	0.00733	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	3.87e-05	0.00134	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP2A6—esophageal cancer	3.85e-05	0.00134	CbGpPWpGaD
Pralatrexate—Back pain—Methotrexate—esophageal cancer	3.83e-05	0.00725	CcSEcCtD
Pralatrexate—DHFR—Metabolism—SLC52A3—esophageal cancer	3.83e-05	0.00133	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—BLVRB—esophageal cancer	3.83e-05	0.00133	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TGFBR2—esophageal cancer	3.79e-05	0.00132	CbGpPWpGaD
Pralatrexate—Decreased appetite—Capecitabine—esophageal cancer	3.77e-05	0.00715	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—CDKN1A—esophageal cancer	3.75e-05	0.0013	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCND1—esophageal cancer	3.75e-05	0.0013	CbGpPWpGaD
Pralatrexate—Vomiting—Cisplatin—esophageal cancer	3.75e-05	0.00709	CcSEcCtD
Pralatrexate—Fatigue—Capecitabine—esophageal cancer	3.74e-05	0.00709	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	3.73e-05	0.00129	CbGpPWpGaD
Pralatrexate—Rash—Cisplatin—esophageal cancer	3.71e-05	0.00703	CcSEcCtD
Pralatrexate—Constipation—Capecitabine—esophageal cancer	3.71e-05	0.00703	CcSEcCtD
Pralatrexate—Dermatitis—Cisplatin—esophageal cancer	3.71e-05	0.00702	CcSEcCtD
Pralatrexate—Anaemia—Methotrexate—esophageal cancer	3.66e-05	0.00693	CcSEcCtD
Pralatrexate—FPGS—Metabolism—ENO1—esophageal cancer	3.65e-05	0.00127	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS1—esophageal cancer	3.65e-05	0.00127	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CYP1B1—esophageal cancer	3.65e-05	0.00127	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	3.63e-05	0.00126	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PSME1—esophageal cancer	3.6e-05	0.00125	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PSME2—esophageal cancer	3.6e-05	0.00125	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SMAD4—esophageal cancer	3.59e-05	0.00124	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—NOS2—esophageal cancer	3.58e-05	0.00124	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—MYC—esophageal cancer	3.57e-05	0.00124	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—BUB1B—esophageal cancer	3.56e-05	0.00123	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Capecitabine—esophageal cancer	3.55e-05	0.00672	CcSEcCtD
Pralatrexate—Leukopenia—Methotrexate—esophageal cancer	3.55e-05	0.00671	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	3.51e-05	0.00122	CbGpPWpGaD
Pralatrexate—Nausea—Cisplatin—esophageal cancer	3.5e-05	0.00662	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—PSME1—esophageal cancer	3.5e-05	0.00121	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—PSME2—esophageal cancer	3.5e-05	0.00121	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MAD2L1—esophageal cancer	3.48e-05	0.00121	CbGpPWpGaD
Pralatrexate—Cough—Methotrexate—esophageal cancer	3.46e-05	0.00654	CcSEcCtD
Pralatrexate—Body temperature increased—Capecitabine—esophageal cancer	3.43e-05	0.0065	CcSEcCtD
Pralatrexate—Abdominal pain—Capecitabine—esophageal cancer	3.43e-05	0.0065	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CYP19A1—esophageal cancer	3.43e-05	0.00119	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PSME1—esophageal cancer	3.41e-05	0.00118	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PSME2—esophageal cancer	3.41e-05	0.00118	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FKBP1A—esophageal cancer	3.38e-05	0.00117	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	3.36e-05	0.00117	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	3.35e-05	0.00116	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—BLVRB—esophageal cancer	3.34e-05	0.00116	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC52A3—esophageal cancer	3.34e-05	0.00116	CbGpPWpGaD
Pralatrexate—DHFR—Disease—WIF1—esophageal cancer	3.31e-05	0.00115	CbGpPWpGaD
Pralatrexate—DHFR—Disease—DOCK2—esophageal cancer	3.31e-05	0.00115	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCND1—esophageal cancer	3.27e-05	0.00113	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC10A2—esophageal cancer	3.26e-05	0.00113	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CA1—esophageal cancer	3.26e-05	0.00113	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TGFBR2—esophageal cancer	3.22e-05	0.00112	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BUB1B—esophageal cancer	3.18e-05	0.0011	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Methotrexate—esophageal cancer	3.17e-05	0.00599	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	3.16e-05	0.0011	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—HMOX1—esophageal cancer	3.13e-05	0.00109	CbGpPWpGaD
Pralatrexate—Asthenia—Capecitabine—esophageal cancer	3.12e-05	0.0059	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—MYC—esophageal cancer	3.11e-05	0.00108	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—BUB1B—esophageal cancer	3.11e-05	0.00108	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP1B1—esophageal cancer	3.1e-05	0.00108	CbGpPWpGaD
Pralatrexate—Anorexia—Methotrexate—esophageal cancer	3.08e-05	0.00583	CcSEcCtD
Pralatrexate—Pruritus—Capecitabine—esophageal cancer	3.07e-05	0.00582	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	3.06e-05	0.00106	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SMAD4—esophageal cancer	3.05e-05	0.00106	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—PSME2—esophageal cancer	3.05e-05	0.00106	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—PSME1—esophageal cancer	3.05e-05	0.00106	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CSNK1A1—esophageal cancer	3.05e-05	0.00106	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CHEK2—esophageal cancer	3.03e-05	0.00105	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ABCB1—esophageal cancer	3.01e-05	0.00104	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—esophageal cancer	3.01e-05	0.00104	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CA2—esophageal cancer	2.98e-05	0.00103	CbGpPWpGaD
Pralatrexate—Diarrhoea—Capecitabine—esophageal cancer	2.97e-05	0.00562	CcSEcCtD
Pralatrexate—SLC19A1—Disease—HIF1A—esophageal cancer	2.94e-05	0.00102	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP19A1—esophageal cancer	2.92e-05	0.00101	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	2.89e-05	0.001	CbGpPWpGaD
Pralatrexate—Dyspnoea—Methotrexate—esophageal cancer	2.88e-05	0.00546	CcSEcCtD
Pralatrexate—TYMS—Metabolism—CA1—esophageal cancer	2.84e-05	0.000986	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC10A2—esophageal cancer	2.84e-05	0.000986	CbGpPWpGaD
Pralatrexate—Decreased appetite—Methotrexate—esophageal cancer	2.81e-05	0.00532	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.8e-05	0.000973	CbGpPWpGaD
Pralatrexate—Fatigue—Methotrexate—esophageal cancer	2.79e-05	0.00528	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—BUB1B—esophageal cancer	2.78e-05	0.000963	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PLCE1—esophageal cancer	2.77e-05	0.00096	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ADH7—esophageal cancer	2.77e-05	0.00096	CbGpPWpGaD
Pralatrexate—Vomiting—Capecitabine—esophageal cancer	2.76e-05	0.00523	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	2.74e-05	0.000951	CbGpPWpGaD
Pralatrexate—Rash—Capecitabine—esophageal cancer	2.74e-05	0.00518	CcSEcCtD
Pralatrexate—Dermatitis—Capecitabine—esophageal cancer	2.74e-05	0.00518	CcSEcCtD
Pralatrexate—SLC19A1—Disease—NOS2—esophageal cancer	2.67e-05	0.000927	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—HMOX1—esophageal cancer	2.66e-05	0.000924	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NOTCH1—esophageal cancer	2.65e-05	0.000918	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Methotrexate—esophageal cancer	2.64e-05	0.005	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—CHEK2—esophageal cancer	2.64e-05	0.000916	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—esophageal cancer	2.62e-05	0.00091	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CA2—esophageal cancer	2.6e-05	0.000901	CbGpPWpGaD
Pralatrexate—Nausea—Capecitabine—esophageal cancer	2.58e-05	0.00488	CcSEcCtD
Pralatrexate—DHFR—Disease—ELMO1—esophageal cancer	2.56e-05	0.000889	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ABCB1—esophageal cancer	2.56e-05	0.000886	CbGpPWpGaD
Pralatrexate—Abdominal pain—Methotrexate—esophageal cancer	2.56e-05	0.00484	CcSEcCtD
Pralatrexate—Body temperature increased—Methotrexate—esophageal cancer	2.56e-05	0.00484	CcSEcCtD
Pralatrexate—DHFR—Disease—TPI1—esophageal cancer	2.51e-05	0.000869	CbGpPWpGaD
Pralatrexate—DHFR—Disease—GSTO1—esophageal cancer	2.51e-05	0.000869	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HIF1A—esophageal cancer	2.5e-05	0.000866	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.48e-05	0.000859	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ADH1B—esophageal cancer	2.43e-05	0.000842	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ADH7—esophageal cancer	2.42e-05	0.000838	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PLCE1—esophageal cancer	2.42e-05	0.000838	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ALDOB—esophageal cancer	2.4e-05	0.000833	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CREBBP—esophageal cancer	2.4e-05	0.000832	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.4e-05	0.000831	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TYMP—esophageal cancer	2.32e-05	0.000805	CbGpPWpGaD
Pralatrexate—Asthenia—Methotrexate—esophageal cancer	2.32e-05	0.00439	CcSEcCtD
Pralatrexate—DHFR—Disease—HIST1H2BM—esophageal cancer	2.31e-05	0.000802	CbGpPWpGaD
Pralatrexate—DHFR—Disease—GAPDH—esophageal cancer	2.31e-05	0.000802	CbGpPWpGaD
Pralatrexate—Pruritus—Methotrexate—esophageal cancer	2.29e-05	0.00433	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.28e-05	0.000791	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NOS2—esophageal cancer	2.27e-05	0.000788	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP26A1—esophageal cancer	2.26e-05	0.000783	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NOTCH1—esophageal cancer	2.25e-05	0.00078	CbGpPWpGaD
Pralatrexate—Diarrhoea—Methotrexate—esophageal cancer	2.21e-05	0.00419	CcSEcCtD
Pralatrexate—DHFR—Metabolism—ALOX15—esophageal cancer	2.2e-05	0.000763	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—EP300—esophageal cancer	2.19e-05	0.000759	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NOS3—esophageal cancer	2.15e-05	0.000745	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ADH1B—esophageal cancer	2.12e-05	0.000735	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTO1—esophageal cancer	2.1e-05	0.000728	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TPI1—esophageal cancer	2.1e-05	0.000728	CbGpPWpGaD
Pralatrexate—Vomiting—Methotrexate—esophageal cancer	2.06e-05	0.00389	CcSEcCtD
Pralatrexate—DHFR—Disease—XIAP—esophageal cancer	2.04e-05	0.000709	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CREBBP—esophageal cancer	2.04e-05	0.000707	CbGpPWpGaD
Pralatrexate—Rash—Methotrexate—esophageal cancer	2.04e-05	0.00386	CcSEcCtD
Pralatrexate—Dermatitis—Methotrexate—esophageal cancer	2.04e-05	0.00385	CcSEcCtD
Pralatrexate—TYMS—Metabolism—TYMP—esophageal cancer	2.03e-05	0.000702	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ALDOB—esophageal cancer	2.01e-05	0.000698	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CREBBP—esophageal cancer	2.01e-05	0.000697	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERBB2—esophageal cancer	2.01e-05	0.000697	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.99e-05	0.000689	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP26A1—esophageal cancer	1.97e-05	0.000683	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTGS2—esophageal cancer	1.96e-05	0.000681	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.94e-05	0.000674	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GAPDH—esophageal cancer	1.94e-05	0.000672	CbGpPWpGaD
Pralatrexate—Nausea—Methotrexate—esophageal cancer	1.92e-05	0.00363	CcSEcCtD
Pralatrexate—TYMS—Metabolism—ALOX15—esophageal cancer	1.92e-05	0.000666	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CRABP1—esophageal cancer	1.92e-05	0.000666	CbGpPWpGaD
Pralatrexate—DHFR—Disease—B2M—esophageal cancer	1.9e-05	0.000659	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—RB1—esophageal cancer	1.85e-05	0.000642	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—TPI1—esophageal cancer	1.83e-05	0.000635	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTO1—esophageal cancer	1.83e-05	0.000635	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NOS3—esophageal cancer	1.83e-05	0.000633	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GNG7—esophageal cancer	1.83e-05	0.000633	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ENO1—esophageal cancer	1.82e-05	0.000631	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—NOS3—esophageal cancer	1.8e-05	0.000624	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PSME1—esophageal cancer	1.79e-05	0.000622	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PSME2—esophageal cancer	1.79e-05	0.000622	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ALDOB—esophageal cancer	1.76e-05	0.000609	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CALR—esophageal cancer	1.72e-05	0.000597	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN1A—esophageal cancer	1.72e-05	0.000596	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ALDH2—esophageal cancer	1.71e-05	0.000593	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CREBBP—esophageal cancer	1.71e-05	0.000592	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB2—esophageal cancer	1.71e-05	0.000592	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GAPDH—esophageal cancer	1.69e-05	0.000586	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.69e-05	0.000585	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CRABP1—esophageal cancer	1.68e-05	0.000581	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTGS2—esophageal cancer	1.67e-05	0.000579	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FBXW7—esophageal cancer	1.67e-05	0.000578	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—RB1—esophageal cancer	1.65e-05	0.000574	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—esophageal cancer	1.65e-05	0.000571	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EP300—esophageal cancer	1.63e-05	0.000567	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.63e-05	0.000566	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTT1—esophageal cancer	1.63e-05	0.000564	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	1.63e-05	0.000564	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—RB1—esophageal cancer	1.62e-05	0.00056	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP2A6—esophageal cancer	1.61e-05	0.000558	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GNG7—esophageal cancer	1.59e-05	0.000553	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—esophageal cancer	1.57e-05	0.000543	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—NOS3—esophageal cancer	1.53e-05	0.00053	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS1—esophageal cancer	1.53e-05	0.000529	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ENO1—esophageal cancer	1.53e-05	0.000529	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PSME2—esophageal cancer	1.5e-05	0.000521	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PSME1—esophageal cancer	1.5e-05	0.000521	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ALDH2—esophageal cancer	1.49e-05	0.000518	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN1A—esophageal cancer	1.46e-05	0.000506	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2A—esophageal cancer	1.45e-05	0.000504	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—RB1—esophageal cancer	1.44e-05	0.000501	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—esophageal cancer	1.42e-05	0.000494	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTT1—esophageal cancer	1.42e-05	0.000492	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	1.42e-05	0.000492	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP2A6—esophageal cancer	1.4e-05	0.000487	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS2—esophageal cancer	1.4e-05	0.000485	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGFR—esophageal cancer	1.39e-05	0.000483	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EP300—esophageal cancer	1.39e-05	0.000482	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—esophageal cancer	1.37e-05	0.000477	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—EP300—esophageal cancer	1.37e-05	0.000475	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TGFBR2—esophageal cancer	1.35e-05	0.000467	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ENO1—esophageal cancer	1.33e-05	0.000461	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS1—esophageal cancer	1.33e-05	0.000461	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	1.33e-05	0.000461	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PSME2—esophageal cancer	1.31e-05	0.000455	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PSME1—esophageal cancer	1.31e-05	0.000455	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP1B1—esophageal cancer	1.3e-05	0.00045	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SMAD4—esophageal cancer	1.28e-05	0.000442	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2A—esophageal cancer	1.27e-05	0.00044	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—EP300—esophageal cancer	1.27e-05	0.000439	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—esophageal cancer	1.23e-05	0.000426	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP19A1—esophageal cancer	1.22e-05	0.000423	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—esophageal cancer	1.21e-05	0.00042	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CA—esophageal cancer	1.21e-05	0.000419	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—esophageal cancer	1.2e-05	0.000416	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN1A—esophageal cancer	1.19e-05	0.000412	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGFR—esophageal cancer	1.18e-05	0.000411	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—EP300—esophageal cancer	1.16e-05	0.000404	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	1.16e-05	0.000402	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP1B1—esophageal cancer	1.13e-05	0.000392	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—EP300—esophageal cancer	1.13e-05	0.000392	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—HMOX1—esophageal cancer	1.11e-05	0.000386	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—EP300—esophageal cancer	1.1e-05	0.000383	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—esophageal cancer	1.1e-05	0.000382	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—esophageal cancer	1.07e-05	0.000372	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ABCB1—esophageal cancer	1.07e-05	0.00037	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP19A1—esophageal cancer	1.06e-05	0.000369	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HIF1A—esophageal cancer	1.04e-05	0.000362	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN1A—esophageal cancer	1.04e-05	0.00036	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CA—esophageal cancer	1.03e-05	0.000356	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CA—esophageal cancer	1.01e-05	0.000351	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—EP300—esophageal cancer	9.87e-06	0.000342	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—esophageal cancer	9.86e-06	0.000342	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—HMOX1—esophageal cancer	9.71e-06	0.000337	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—esophageal cancer	9.62e-06	0.000334	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NOS2—esophageal cancer	9.49e-06	0.000329	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NOTCH1—esophageal cancer	9.4e-06	0.000326	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ABCB1—esophageal cancer	9.32e-06	0.000323	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CA—esophageal cancer	8.61e-06	0.000298	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—esophageal cancer	8.6e-06	0.000298	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CREBBP—esophageal cancer	8.52e-06	0.000296	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—esophageal cancer	8.1e-06	0.000281	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NOS3—esophageal cancer	7.63e-06	0.000265	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CREBBP—esophageal cancer	7.14e-06	0.000247	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB2—esophageal cancer	7.14e-06	0.000247	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—esophageal cancer	7.06e-06	0.000245	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—esophageal cancer	6.98e-06	0.000242	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NOS3—esophageal cancer	6.39e-06	0.000222	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CREBBP—esophageal cancer	6.23e-06	0.000216	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN1A—esophageal cancer	6.1e-06	0.000212	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—esophageal cancer	5.84e-06	0.000203	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EP300—esophageal cancer	5.8e-06	0.000201	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NOS3—esophageal cancer	5.58e-06	0.000193	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—esophageal cancer	5.1e-06	0.000177	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—esophageal cancer	5.06e-06	0.000175	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—esophageal cancer	4.95e-06	0.000172	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—EP300—esophageal cancer	4.86e-06	0.000169	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CA—esophageal cancer	4.29e-06	0.000149	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—EP300—esophageal cancer	4.24e-06	0.000147	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CA—esophageal cancer	3.6e-06	0.000125	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CA—esophageal cancer	3.14e-06	0.000109	CbGpPWpGaD
